Your Cart
Your cart is empty

Looks like you haven't added any test / checkup to your cart

Add Test / Checkup
User Sign In Health checkup offers
Lab Test

EGFR Mutation Detection

EGFR mutation detection is a diagnostic procedure that plays a critical role in the management of non- small cell lung cancer (NSCLC). EGFR, or Epidermal Growth Factor Receptor, is a protein found on the surface of some cells and is involved in cell growth and division. Mutations in the EGFR gene can cause the receptor to malfunction, leading to the uncontrolled growth of cancer cells. The EGFR Mutation Detection test using Real Time PCR for Exon 18, 19, 20, 21 including T790M, is an FDA-approved assay that aids in identifying these mutations, thereby guiding the most effective treatment approach.

  • Test Name EGFR Mutation Detection - Real Time PCR (Exon 18, 19, 20, 21) Including T790M-USFDA Approved Kit
  • Sample Type Tumor Tissue.
  • Preparations Required For tissue samples, follow your doctor's instructions regarding biopsy procedures.
  • Report Time 7 days

The test is performed on tumor tissue samples obtained through a biopsy or blood samples. It is designed to detect specific mutations in the EGFR gene, particularly in Exon 18, 19, 20, and 21, which are common in non-small cell lung cancer. Among these, the T790M mutation is especially significant as it is associated with resistance to certain EGFR-targeting therapies.

Home Sample Collection Process

Book your convenient slot
Book your convenient slot
Sample Collection by Phlebotomist
Sample Collection by Phlebotomist
Reporting of the sample at lab
Reporting of the sample at lab
Download Reports
Download Reports
Frequently Asked Questions

The EGFR Mutation Detection test is a diagnostic procedure used to identify mutations in the EGFR gene, particularly in patients with non-small cell lung cancer. The test helps in determining the most suitable targeted therapy for the patient.

EGFR mutations are common in NSCLC and their presence can influence the progression of the disease and response to therapy. Detecting these mutations helps in selecting the most appropriate targeted therapy, which can be more effective and have fewer side effects than conventional chemotherapy.

Exons 18, 19, 20, and 21 are regions of the EGFR gene where mutations are commonly found in NSCLC. These mutations can result in altered protein functions that contribute to cancer development and progression. Identifying mutations in these exons can be crucial for selecting targeted therapies.

The T790M mutation is a specific change in the EGFR gene that is associated with resistance to certain EGFR inhibitors. Detecting the T790M mutation can help in identifying patients who may benefit from alternative treatments.

The test is performed on a sample of tumor tissue or blood. The DNA is extracted and then analyzed using Real Time PCR to detect specific mutations in the EGFR gene.

No specific preparation is needed for the blood sample. For tissue samples, your doctor will provide instructions regarding the biopsy procedure.

If mutations in the EGFR gene are detected, especially in exons 18, 19, 20, or 21, it can indicate that the patient may benefit from targeted therapy that specifically addresses these mutations. The test also helps in monitoring resistance to treatment, particularly in the case of the T790M mutation.

Yes, the test may not detect all mutations in the EGFR gene and is mainly focused on the most common ones associated with NSCLC. Also, a negative result does not rule out the presence of EGFR mutations not covered by this test.

A positive result means that a mutation in the EGFR gene has been detected. This information can be used to guide treatment decisions, such as the use of targeted therapies.

The quality of the sample, the stage of cancer, and the presence of other mutations or genetic variations can affect the test results.

Coverage for the EGFR Mutation Detection test can vary depending on your health insurance plan. It is recommended to check with your insurance provider for details regarding coverage.

If you have an abnormal EGFR Mutation Detection result, it is important to consult an oncologist, who specializes in cancer treatment, to discuss the implications of the results and the available treatment options.

The frequency of this test should be determined by your doctor based on your health status and response to therapy.

Yes, there are alternative tests such as Next-Generation Sequencing (NGS) that can detect a broader range of mutations including EGFR.

Yes, though it is primarily used for NSCLC, it can also be used in other cancers where EGFR mutations play a role.

Understanding the genetic makeup of a tumor can be a powerful tool in battling cancer. The EGFR Mutation Detection test provides critical information that can guide treatment decisions for patients with non-small cell lung cancer. By identifying specific mutations, particularly in the EGFR gene, doctors can personalize treatment plans to target the genetic changes driving the cancer, potentially leading to more effective treatment with fewer side effects. Consultation with an oncologist is crucial for interpreting the results and making informed treatment choices.

EGFR Mutation Detection - Real time PCR ( Exon 18,19,20,21) including T790M- USFDA approved Kit
₹ 8500 Add to Cart
Schedule Test in Your Available Time
Locations Near You in Hyderabad
  • 4KM from Madhapur
  • 3KM from Banjara Hills
  • 1.9KM from Yusufguda
  • 3KM from Madhura Nagar
  • 5KM from Shaikpet